Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733 (2020).

Li, Q. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. 382, 1199–1207 (2020).

Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).

Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269 (2020).

Anand, K. et al. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra α-helical domain. EMBO J. 21, 3213–3224 (2002).

Yang, H. et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl Acad. Sci. USA 100, 13190–13195 (2003).

de Wit, E., van Doremalen, N., Falzarano, D. & Munster, V. J. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14, 523–534 (2016).

Hegyi, A. & Ziebuhr, J. Conservation of substrate specificities among coronavirus main proteases. J. Gen. Virol. 83, 595–599 (2002).

Pillaiyar, T., Manickam, M., Namasivayam, V., Hayashi, Y. & Jung, S. H. An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy. J. Med. Chem. 59, 6595–6628 (2016).

Xue, X. et al. Production of authentic SARS-CoV Mpro with enhanced activity: application as a novel tag-cleavage endopeptidase for protein overproduction. J. Mol. Biol. 366, 965–975 (2007).

Wang, Q. M., Johnson, R. B., Cox, G. A., Villarreal, E. C. & Loncharich, R. J. A continuous colorimetric assay for rhinovirus-14 3C protease using peptide p-nitroanilides as substrates. Anal. Biochem. 252, 238–245 (1997).

Yang, H. et al. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol. 3, e324 (2005).

Xue, X. et al. Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design. J. Virol. 82, 2515–2527 (2008).

Ren, Z. et al. The newly emerged SARS-like coronavirus HCoV-EMC also has an “Achilles’ heel”: current effective inhibitor targeting a 3C-like protease. Protein Cell 4, 248–250 (2013).

Wang, F., Chen, C., Tan, W., Yang, K. & Yang, H. Structure of main protease from human coronavirus NL63: insights for wide spectrum anti-coronavirus drug design. Sci. Rep. 6, 22677 (2016).

Zhao, Q. et al. Structure of the main protease from a global infectious human coronavirus, HCoV-HKU1. J. Virol. 82, 8647–8655 (2008).

Lee, C.-C. et al. Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds. J. Biol. Chem. 284, 7646–7655 (2009).

St John, S. E., Tomar, S., Stauffer, S. R. & Mesecar, A. D. Targeting zoonotic viruses: structure-based inhibition of the 3C-like protease from bat coronavirus HKU4—the likely reservoir host to the human coronavirus that causes Middle East respiratory syndrome (MERS). Bioorg. Med. Chem. 23, 6036–6048 (2015).

Wang, F. et al. Crystal structure of feline infectious peritonitis virus main protease in complex with synergetic dual inhibitors. J. Virol. 90, 1910–1917 (2016).

Wang, F. et al. Michael acceptor-based peptidomimetic inhibitor of main protease from porcine epidemic diarrhea virus. J. Med. Chem. 60, 3212–3216 (2017).

Cui, W. et al. The crystal structure of main protease from mouse hepatitis virus A59 in complex with an inhibitor. Biochem. Biophys. Res. Commun. 511, 794–799 (2019).

Friesner, R. A. et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47, 1739–1749 (2004).

Rubin, B. & Waugh, M. H. Antiphlogistic effects of antiserotonin (SQ 10,643) and aminopyrine in rats versus endotoxin and other agents. Proc. Soc. Exp. Biol. Med. 119, 438–443 (1965).

Chen, L. et al. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. J. Virol. 79, 7095–7103 (2005).

Feng, B. Y. & Shoichet, B. K. A detergent-based assay for the detection of promiscuous inhibitors. Nat. Protocols 1, 550–553 (2006).

Singh, N. et al. A safe lithium mimetic for bipolar disorder. Nat. Commun. 4, 1332 (2013).

Lynch, E. & Kil, J. Development of ebselen, a glutathione peroxidase mimic, for the prevention and treatment of noise-induced hearing loss. Semin. Hear. 30, 047–055 (2009).

Kil, J. et al. Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 390, 969–979 (2017).

Renson, M., Etschenberg, E. & Winkelmann, J. 2-Phenyl-1, 2-benzisoselenazol-3 (2H)-one containing pharmaceutical preparations and process for the treatment of rheumatic diseases. US patent 4, 352, 799 (1982).

Masaki, C. et al. Effects of the potential lithium-mimetic, ebselen, on impulsivity and emotional processing. Psychopharmacology (Berl.) 233, 2655–2661 (2016).

Xu, M. et al. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat. Med. 22, 1101–1107 (2016).

Aulner, N., Danckaert, A., Ihm, J., Shum, D. & Shorte, S. L. Next-generation phenotypic screening in early drug discovery for infectious diseases. Trends Parasitol. 35, 559–570 (2019).

Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R. & Hilgenfeld, R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 300, 1763–1767 (2003).

Winter, G. xia2: an expert system for macromolecular crystallography data reduction. J. Appl. Crystallogr. 43, 186–190 (2010).

McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).

Potterton, L. et al. CCP4i2: the new graphical user interface to the CCP4 program suite. Acta Crystallogr. D 74, 68–84 (2018).

Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486–501 (2010).

Afonine, P. V. et al. Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. D 68, 352–367 (2012).

Greenwood, J. R., Calkins, D., Sullivan, A. P. & Shelley, J. C. Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution. J. Comput. Aided Mol. Des. 24, 591–604 (2010).

Bai, F. et al. Free energy landscape for the binding process of huperzine A to acetylcholinesterase. Proc. Natl Acad. Sci. USA 110, 4273–4278 (2013).

Liu, X., Jiang, H. & Li, H. SHAFTS: a hybrid approach for 3D molecular similarity calculation. 1. Method and assessment of virtual screening. J. Chem. Inf. Model. 51, 2372–2385 (2011).

Guimarães, C. R. W. & Cardozo, M. MM-GB/SA rescoring of docking poses in structure-based lead optimization. J. Chem. Inf. Model. 48, 958–970 (2008).

Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269–271 (2020).